癌の分類・記載法として、本邦で広く使用されている癌取扱い規約。諸外国との交流が進む大腸癌診療において、規約をもとに収集されたデータによる研究成果の海外発信や海外の読者による論文の理解のために、英語版の刊行が求められている。日本語版規約第7版補訂版準拠の英語版第2版（2009年）より10年ぶりの改訂となる本版は、『大腸癌取扱い規約第9版』（2018年7月）に準拠した全文英訳版である。

Table of Contents
The principles of revision and changes from the previous edition（the 8th Japanese edition）.
I. Guidelines for classification
1　Aims and subjects
　1.1　Aims
　1.2　Subjects
2　General principles of description methods
　2.1　Clinical, surgical, and pathological findings
　2.2　Findings following preoperative treatment
　2.3　Findings of recurrence
3　Recording of findings
　3.1　Primary tumors
　　3.1.1　Tumor location
　　3.1.2　Anatomical divisions of colon and rectum, vermiform appendix, and anal canal
　　3.1.3　Circumferential divisions of the wall of the rectum and anal canal
　　3.1.4　Number and size of lesions and proportion of the tumor in relation to the circumference of the bowel
　　3.1.5　Macroscopic types
　　3.1.6　Depth of tumor invasion（T）
　3.2　Metastasis
　　3.2.1　Lymph node metastasis
　　3.2.2　Distant metastasis（M）
　3.3　Stage grouping
　　3.3.1　Clinical and pathological classifications for stage grouping
　　3.3.2　Stage grouping following preoperative treatment
　3.4　Multiple colorectal cancers, multiple primary cancers
　3.5　Family history and hereditary diseases
4　Endoscopic and surgical treatments
　4.1　Endoscopic treatment
　　4.1.1　Endoscopic treatment method
　4.2 Surgical treatment
　　4.2.1　Approach to the lesion
　　4.2.2　Surgical procedures
　　4.2.3　Lymph node dissection
　　4.2.4　Anastomosis
　　4.2.5　Combined resection of adjacent organs and structures
　　4.2.6　Preservation of autonomic nerves（AN）
5　Assessment of cancer involvement at resected margin, residual tumor, and curability
　5.1　Cancer involvement at resection margins
　　5.1.1　Specimens obtained by endoscopic resection
　　5.1.2　Specimens obtained by surgical resection
　5.2　Residual tumor
　　5.2.1　Residual tumor following endoscopic treatment（ER）
　　5.2.2　Residual tumor following surgical treatment（R）
　5.3　Curability
6　Chemotherapy and radiotherapy
　6.1　Chemotherapy documentation
　6.2　Radiotherapy documentation
　　6.2.1　Aims of radiotherapy
　　6.2.2　Methods of radiotherapy
　　6.2.3　Radiation field
7　Evaluation of resected specimens
　7.1　Macroscopic findings
　　7.1.1　Tumor location
　　7.1.2　Macroscopic types
　　7.1.3　Size
　7.1.4　Proportion of the tumor in relation to the circumference of the bowel
　　7.1.5　Distance from the lesion to the resection margin
　　7.1.6　Extent and properties of invasion and metastasis
　　7.1.7　Depth of tumor invasion
　　7.1.8　Lymph node metastasis and location
　7.2　Histological findings
　　7.2.1　Histological types
　　7.2.2　Infiltration pattern（INF）
　　7.2.3　Lymphovascular invasion
　　7.2.4　Tumor budding（BD）
　　7.2.5　Extramural cancer deposits without lymph node structure（EX）
　　7.2.6　Perineural invasion（Pn）
　7.3　Histological criteria for the assessment of response to chemotherapy/rediotherapy
　7.4　Histological assessment of biopsy specimens（Group classification）
　7.5　Measurement of the depth of invasion
　　7.5.1　T1 cancer
　　7.5.2　Tumor invasion beyond the MP in sites without the serosa
8　Treatment outcome record
　8.1　Number of patients
　8.2　Multiple colorectal cancers, multiple primary cancers
　8.3　Modalities of treatment and adjuvant therapy
　8.4　Total number of colorectal cancer cases with treatment, and the number and rate of cases by treatment types
　　8.4.1　Resection rate
　　8.4.2　Endoscopic treatment
　　8.4.3　Chemotherapy and radiotherapy
　8.5　Number and rate of operative mortality
　8.6　Number and rate of hospital mortality following surgery
　8.7　Survival analysis
　　8.7.1　Survival
　　8.7.2　Recurrence/metastasis; site（s）and mode
　　8.7.3　Survival analysis method
Supplement: Lymph node groups and station number
Supplementary Reference of Macroscopic Types
Supplement: Measurement of submucosal invasion distance
II. Assessment of response to chemotherapy and radiotherapy
1　Assessment of response
2　Definition of efficacy endpoints
　2.1　Response rate
　2.2　Overall survival（OS）, progression-free survival（PFS）, relapse-free survival（RFS）, disease-free survival（DFS）, time to treatment failure（TTF）
3　Documentation of adverse events
III. Explanation of pathological items［Supplement: Histology Atlas］
1　Histological types
2　Histological assessment of biopsy specimens（Group classification）
3　Handling of resected specimens
　3.1　Handling of biopsy materials
　3.2　Macroscopic examination and handling of surgically resected specimens
　3.3　Handling of endoscopically resected specimens
Supplementary histology atlas
Supplements
　Supplement 1 TNM Classification of malignant tumours
　Supplement 2 Summary of findings
　Supplement 3 Checklist for pathological report
　Supplement 4 List of abbreviations